ArticleAmerican journal of epidemiology2012
Interpreting incremental value of markers added to risk prediction models.
Article in American journal of epidemiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 264 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
264 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- External validation of prognostic models for chronic kidney disease among type 2 diabetes.Journal of nephrology · 2022Pooled it
- Pooled it
- A methodology review on the incremental prognostic value of computed tomography biomarkers in addition to Framingham risk score in predicting cardiovascular disease: the use of association, discrimination and reclassification.BMC cardiovascular disorders · 2018Pooled it
- Development and validation of a nomogram model for prediction of stroke-associated pneumonia associated with intracerebral hemorrhage.BMC geriatrics · 2023Trial
- Improvement in the Prediction of Cerebrovascular Events With White Matter Hyperintensity.Journal of the American Heart Association · 2023Trial
- Derivation and validation of the ISAR score to predict the risk of repeat percutaneous coronary intervention for recurrent drug-eluting stent restenosis.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Trial
- Novel urinary glycan profiling by lectin array serves as the biomarkers for predicting renal prognosis in patients with IgA nephropathy.Scientific reports · 2021Trial
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines.JAMA cardiology · 2020 · on this mapTrial
- Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease.The Journal of clinical investigation · 2020Trial
- Association of Obesity With Septic Complications After Major Abdominal Surgery: A Secondary Analysis of the RELIEF Randomized Clinical Trial.JAMA network open · 2019Trial
- Integrated prediction of lesion-specific ischaemia from quantitative coronary CT angiography using machine learning: a multicentre study.European radiology · 2018Trial
- Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.JAMA cardiology · 2018Trial
- N-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population.The Journal of clinical endocrinology and metabolism · 2016Trial
- Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians.Genetics in medicine : official journal of the American College of Medical Genetics · 2016Trial
- Genome-scale perturbation signatures from primary human CD4bioRxiv : the preprint server for biology · 2026Article
- Age-Adjusted Phenome-Wide Analysis Identifies Liver Enzymes and Lipid Markers Associated with Prevalent Breast Cancer in the Qatar Biobank.Journal of epidemiology and global health · 2026Article
- Letter: Defining the Incremental Predictive Value of HBsAg in Hepatocellular Carcinoma Risk Prediction.Alimentary pharmacology & therapeutics · 2026Article
- Letter: Defining the Incremental Predictive Value of HBsAg in Hepatocellular Carcinoma Risk Prediction, Authors' Reply.Alimentary pharmacology & therapeutics · 2026Article
- Reconstruction of Imagined Melody with Relative Pitch Decoding in Electrocorticography.eNeuro · 2026Article
204 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
The discrimination of a risk prediction model measures that model's ability to distinguish between subjects with and without events. The area under the receiver operating characteristic curve (AUC) is a popular measure of discrimination. However, the AUC has recently been criticized for its insensitivity in model comparisons in which the baseline model has performed well. Thus, 2 other measures have been proposed to capture improvement in discrimination for nested models: the integrated discrimination improvement and the continuous net reclassification improvement. In the present study, the authors use mathematical relations and numerical simulations to quantify the improvement in discrimination offered by candidate markers of different strengths as measured by their effect sizes. They demonstrate that the increase in the AUC depends on the strength of the baseline model, which is true to a lesser degree for the integrated discrimination improvement. On the other hand, the continuous net reclassification improvement depends only on the effect size of the candidate variable and its correlation with other predictors. These measures are illustrated using the Framingham model for incident atrial fibrillation. The authors conclude that the increase in the AUC, integrated discrimination improvement, and net reclassification improvement offer complementary information and thus recommend reporting all 3 alongside measures characterizing the performance of the final model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.